Molecular iodine inhibits the expression of stemness markers on cancer stem-like cells of established cell lines derived from cervical cancer

• Published in: BMC cancer Vol. 18; no. 1; p. 928
• Main Authors: Bigoni-Ordóñez, Gabriele Davide, Ortiz-Sánchez, Elizabeth, Rosendo-Chalma, Pedro, Valencia-González, Heriberto A, Aceves, Carmen, García-Carrancá, Alejandro
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 26.09.2018; BioMed Central; BMC
• Subjects: Animal models; Animals; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - pharmacology; Biomarkers, Tumor - metabolism; Cancer therapies; Care and treatment; Cell cycle; Cell Line, Tumor; Cell Proliferation - drug effects; Cell self-renewal; Cell Survival - drug effects; Cervical cancer; Cervical cancer stem cells; Cervix; Development and progression; Drug resistance; Female; Gene Expression Regulation, Neoplastic - drug effects; HeLa Cells; Human papillomavirus; Humans; Iodine; Iodine (Chemical element); Iodine - administration & dosage; Iodine - pharmacology; Keratin; KLF4 protein; Metastases; Metastasis; Mice; Molecular iodine; Neoplastic Stem Cells - drug effects; Neoplastic Stem Cells - metabolism; Oct-4 protein; PPAR gamma; Stem cell transplantation; Stem cells; Stemness markers; Supplements; Tumor cell lines; Tumorigenicity; Tumors; Uterine Cervical Neoplasms - drug therapy; Uterine Cervical Neoplasms - metabolism; Xenograft Model Antitumor Assays; Xenografts; Stemness markers; Cervical cancer stem cells; PPAR gamma; Molecular iodine
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-018-4824-5

Cancer stem cells (CSC) are characterized by deregulated self-renewal, tumorigenicity, metastatic potential, aberrant stemness signaling pathways, resistance to conventional therapy, and the ability to give rise to a progeny of proliferating cells that constitute the bulk of tumors. Targeting CSC will provide novel treatments for cancer. Different investigations have focused on developing complementary approaches that involve natural compounds that decrease chemo-resistance and reduce the side effects of conventional therapies. Since, it has been reported that molecular iodine (I ) exhibits antineoplastic effects and decreases tumor progression in some cancer models, we evaluated the potential effect of I on cell cultures enriched in cervical cancer stem-like cells. HeLa and SiHa cervical cancer cells were treated with 200uM I for 24 h. After time, cells were cultured in CSC-conditioned medium (cervospheres) and viability assays were performed. Following, tumorigenic capabilities in cervospheres treated with I were evaluated in NOD/SCID mice. HeLa monolayer cells untreated and their respective cervosphere cells treated or untreated with 200 μM of I for 24 h were xenotransplanted subcutaneously at different amounts and mice were monitored for at least 2 months. In the present study, monolayer and CSC-enriched cultures (cervospheres) from cervical cancer-derived cell lines, HeLa and SiHa, showed that 200uM I supplementation inhibits proliferation of both and decreased their tumorigenic capacity, in vivo. This antineoplastic effect of I was accompanied by diminished expression of stemness markers including CD49f, CK17, OCT-4, NANOG, SOX2, and KLF4, as well as increased expression and activation of PPARγ receptors. All this data led us to suggest a clinical potential use of I for targeting CSC and improve current treatments against cervical cancer.